Today: 30 April 2026
Super Micro Computer stock slides after Goldman’s ‘Sell’ call puts margins back in the spotlight
14 January 2026
2 mins read

Super Micro Computer stock slides after Goldman’s ‘Sell’ call puts margins back in the spotlight

New York, Jan 13, 2026, 20:42 ET — Market closed.

  • Shares of Super Micro Computer dropped 5% Tuesday, ending the day at $28.60
  • Goldman Sachs initiated coverage with a Sell rating, lowering its price target to $26
  • Investors are focused on margin pressure as the company’s next earnings report approaches

Shares of Super Micro Computer dropped 5% on Tuesday after Goldman Sachs issued a bearish call, reigniting concerns over the AI server maker’s profitability.

The timing is crucial since investors have viewed SMCI as a stand-in for AI infrastructure spending. Now, the conversation has moved. It’s not about whether demand is there anymore, but rather who can hold onto margins as hardware turns into a commodity.

As earnings season kicks off and rate expectations lose their grip on high-growth stocks, that question is gaining traction. For Super Micro, the upcoming report needs to prove it can grow without sacrificing too much on pricing.

U.S. stocks slipped on Tuesday, dragged down by financials despite inflation data meeting expectations. “Financials are getting hit by Trump’s credit-card proposal,” noted Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder. Reuters

Goldman Sachs analyst Katherine Murphy initiated coverage on Super Micro with a Sell rating, cutting the 12-month target price to $26 from $34. She acknowledged the company as “a leader in the AI server market” but highlighted “limited visibility” around profit gains. Murphy flagged margin pressure from large, margin-dilutive deals and noted the firm is stuck between a tight customer base and powerful suppliers. Investing.com

Barron’s, referencing a Goldman note, reported that the bank forecasts the company’s gross margin—its take after hardware costs—to drop to about 7.5% in fiscal 2026, down from over 15% in 2022, amid rising costs and stiffer competition.

Super Micro missed quarterly estimates in November due to delivery delays caused by last-minute configuration changes, Reuters reported. About $1.5 billion in revenue got pushed into a future quarter. CEO Charles Liang attributed the hold-up to the added integration and testing demands of new GPU rack systems. Despite this, the company raised its fiscal 2026 sales forecast to at least $36 billion.

The selloff hasn’t been linear. If Super Micro manages to boost margins while shipments increase—or if demand holds firm enough to keep prices steady—Tuesday’s downgrade might be short-lived.

The downside is straightforward: ongoing margin pressure, larger competitors undercutting prices, and the company continuing to secure deals that boost revenue but hurt profits, leaving minimal margin for error.

Macro factors are at play. U.S. consumer prices increased 0.3% in December, maintaining a 2.7% annual rate. This keeps the Federal Reserve on track to hold rates steady at its Jan. 27-28 meeting, according to Reuters.

Traders are set to focus on follow-up analyst calls and any signals from the wider AI hardware supply chain around costs and pricing — the areas that usually impact margins earliest — ahead of the next session.

Super Micro’s upcoming earnings report, pegged by Nasdaq’s earnings calendar for Feb. 24, is the next key event to watch.

Stock Market Today

  • Avalyn Pharma Raises $300M in Nasdaq IPO to Advance Respiratory Drug Pipeline
    April 30, 2026, 4:14 AM EDT. Avalyn Pharma overshot its target with a $300 million initial public offering (IPO) on Nasdaq under ticker AVLN, exceeding expectations from 11.8 million to 16.6 million shares at $18 each. This funding will support late-stage studies of inhaled versions of approved respiratory drugs, including AP01, an inhaled pirfenidone for idiopathic pulmonary fibrosis, and AP02, an inhaled nintedanib derivative. The company also plans to develop AP03, a combination inhaled therapy. With $138.4 million on hand pre-IPO, Avalyn aims to finance multiple pipeline projects. CEO Lyn Baranowski brings respiratory drug development experience, while the IPO reflects broader biotech trends in reformulating approved medications for improved delivery.

Latest article

Australia Stock Market Today: ASX 200 Falls Again as Oil Shock, Woolworths Warning Hit Shares

Australia Stock Market Today: ASX 200 Falls Again as Oil Shock, Woolworths Warning Hit Shares

30 April 2026
Australian shares fell for an eighth straight session Thursday, with the S&P/ASX 200 closing down 0.24% at 8,665.8 as miners and consumer staples dropped. The decline followed data showing annual inflation rose to 4.6% in March, above the Reserve Bank’s target. Woolworths shares slid up to 9.8% after warning on earnings. Oil prices hit a four-year high, lifting energy stocks 1.4%.
CoreWeave stock (CRWV) slips after-hours as CEO bats away Nvidia ‘circular financing’ fears
Previous Story

CoreWeave stock (CRWV) slips after-hours as CEO bats away Nvidia ‘circular financing’ fears

BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP
Next Story

BHP stock ends higher as China’s iron ore surge meets merger talk — what’s next for ASX:BHP

Go toTop